PCP- "Angel dust"
PCP (phencyclidine) was
developed in the 1950s as an intravenous anesthetic. Use of PCP in
humans was discontinued in 1965, because it was found that patients
often became agitated, delusional, and irrational while recovering from
its anesthetic effects. PCP is illegally manufactured in laboratories
and is sold on the street by such names as "angel dust,"
"ozone," "wack," and "rocket fuel."
"Killer joints"and "crystal supergrass" are names
that refer to PCP combined with marijuana. The variety of street names
for PCP reflects its bizarre and volatile effects.
PCP is a white
crystalline powder that is readily soluble in water or alcohol. It has a
distinctive bitter chemical taste. PCP can be mixed easily with dyes and
turns up on the illicit drug market in a variety of tablets, capsules,
and colored powders. It is normally used in one of three ways: snorted,
smoked, or eaten. For smoking, PCP is often applied to a leafy material
such as mint, parsley, oregano, or marijuana.
Health Hazards
PCP is addicting; that
is, its use often leads to psychological dependence, craving, and
compulsive PCP-seeking behavior. It was first introduced as a street
drug in the 1960s and quickly gained a reputation as a drug that could
cause bad reactions and was not worth the risk. Many people, after using
the drug once, will not knowingly use it again. Yet others use it
consistently and regularly. Some persist in using PCP because of its
addicting properties. Others cite feelings of strength, power,
invulnerability and a numbing effect on the mind as reasons for their
continued PCP use.
Many PCP users are
brought to emergency rooms because of PCP's unpleasant psychological
effects or because of overdoses. In a hospital or detention setting,
they often become violent or suicidal, and are very dangerous to
themselves and to others. They should be kept in a calm setting and
should not be left alone.
At low to moderate doses,
physiological effects of PCP include a slight increase in breathing rate
and a more pronounced rise in blood pressure and pulse rate. Respiration
becomes shallow, and flushing and profuse sweating occur. Generalized
numbness of the extremities and muscular incoordination also may occur.
Psychological effects include distinct changes in body awareness,
similar to those associated with alcohol intoxication. Use of PCP among
adolescents may interfere with hormones related to normal growth and
development as well as with the learning process.
At high doses of PCP,
there is a drop in blood pressure, pulse rate, and respiration. This may
be accompanied by nausea, vomiting, blurred vision, flicking up and down
of the eyes, drooling, loss of balance, and dizziness. High doses of PCP
can also cause seizures, coma, and death (though death more often
results from accidental injury or suicide during PCP intoxication).
Psychological effects at high doses include illusions and
hallucinations. PCP can cause effects that mimic the full range of
symptoms of schizophrenia, such as delusions, paranoia, disordered
thinking, a sensation of distance from one's environment, and catatonia.
Speech is often sparse and garbled.
People who use PCP for
long periods report memory loss, difficulties with speech and thinking,
depression, and weight loss. These symptoms can persist up to a year
after cessation of PCP use. Mood disorders also have been reported. PCP
has sedative effects, and interactions with other central nervous system
depressants, such as alcohol and benzodiazepines, can lead to coma or
accidental overdose.
Extent of Use
Monitoring the Future
Study (MTF)*
NIDA's 1997 MTF shows
that use of PCP by high school seniors has declined steadily since 1979,
when 7.0 percent of seniors had used PCP in the year preceding the
survey. In 1997, however, 2.3 percent of seniors used PCP at least once
in the past year, up from a low of 1.2 percent in 1990. Past month use
among seniors decreased from 1.3 percent in 1996 to 0.7 percent in 1997.
Percentage
of 12th-graders who have used PCP:
Monitoring the Future Study
| |
1979
| 1985
| 1991
| 1992
| 1993
| 1994
| 1995
| 1996
| 1997
|
| Ever
Used
| 12.8% |
4.9% |
2.9% |
2.4% |
2.9% |
2.8% |
2.7% |
4.0% |
3.9% |
| Used
in Past Year
| 7.0 |
2.9 |
1.4 |
1.4 |
1.4 |
1.6 |
1.8 |
2.6 |
2.3 |
| Used
in Past Month
| 2.4 |
1.6 |
0.5 |
0.6 |
1.0 |
0.7 |
0.6 |
1.3 |
0.7 |
National Household Survey
on Drug Abuse (NHSDA)**
According to the 1996
NHSDA, 3.2 percent of the population aged 12 and older have used PCP at
least once. Lifetime use of PCP was higher among those aged 26 through
34 (4.2 percent) than for those 18 through 25 (2.3 percent) and those 12
through 17 (1.2 percent).
|